



Attorney Docket No.: 6176.200-US

1F1-
1653
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Serial No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 5, 2004

Csaba Attila Szakolczai
(name of person mailing paper)

Csaba Attila Szakolczai
(signature of person mailing paper)



Attorney Docket No.: 6176.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US 2003/0130191 A1
2. US 2003/0170863 A1
3. US 5,580,560
4. US 5,874,407
5. US 5,994,296
6. US 60/184,036
7. US 10/415,963
8. JP 2001 061479
9. JP 10/59866A
10. WO 88/10295
11. WO 94/07515
12. WO 94/27631
13. WO 97/20939
14. WO 98/31394
15. WO 01/58935 A2
16. WO 01/75086 A2
17. WO 01/82943 A2

11/09/2004 NR04A1 00000052 141447 09848107
01 FC:1806 180.00 DA

18. WO 01/83725 A1
19. WO 01/85198 A1
20. WO 02/22776 A2
21. WO 02/062376 A1
22. WO 02/077218 A1
23. WO 02/38162 A1
24. WO 03/027147 A2
25. Neuenschwander et al., Biochemistry, Vol. 34, pp. 8701-7 (1995)
26. Bernardi et al., Human Mutation, Vol. 8, pp. 108-15 (1996)
27. Chang et al., Biochemistry, Vol. 38, pp. 10940-48 (1999)
28. Leonard et al., Abstract 1474, Journ of Int Soc Thromb and Haemost., pg. 466 (Suppl. 08/99)
29. Iakhiev et al., Thromb and Haemost, Vol. 85 (3), pp. 458-63 (2001)
30. Jin et al., Journ of Mol Bio, Vol. 307 (part 5), pp. 1503-17
31. Persson et al., Journ of Biol Chem, Vol. 276 (31), pp. 29195-9 (2001)
32. International Search Report (08/25/2003)
33. International Search Report (02/05/2004)
34. Peyvandi et al., Throm Haemost, Vol. 84, pp. 250-7 (2000)
35. Peyvandi et al., Throm Haemost, Vol. 88, pp. 750-5 (2002)
36. Soejima et al., Journ of Bio Chem, Vol. 276 (20), pp. 17229-35 (2001)


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Date: November 5, 2004

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Please charge any additional fees, should they be required, to Novo Nordisk® Pharmaceuticals, Inc. Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6176.200-US

Serial No. 09/848,107

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Persson et al.

(Use several sheets if necessary)

Filing Date May 3, 2001

Group 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2003/0130191 A1	10/28/02	Persson et al.			
	2003/0170863 A1	05/03/01	Persson et al.			
	5,580,560	08/22/94	Nicolaisen et al.			
	5,874,407	09/17/97	Kelley et al.			
	5,994,296	03/05/98	Ruf et al.			
	60/184,036	02/22/00				


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	2001 061479	08/24/99	JP				
	10/59866A	03/03/98	JP				
	88/10295	06/25/87	WO				
	94/07515	10/06/92	WO				
	94/27631	05/23/94	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Neuenschwander et al., Biochemistry, Vol. 34, pp. 8701-7 (1995)
		Bernardi et al., Human Mutation, Vol. 8, pp. 108-15 (1996)
		Chang et al., Biochemistry, Vol. 38, pp. 10940-48 (1999)
		Leonard et al., Abstract 1474, Journ of Int Soc Thromb and Haemost., pg. 466 (Suppl. 08/99)
		Iakhiev et al., Thromb and Haemost, Vol. 85 (3), pp. 458-63 (2001)
		Jin et al., Journ of Mol Bio, Vol. 307 (part 5), pp. 1503-17
		Persson et al., Journ of Biol Chem, Vol. 276 (31), pp. 29195-9 (2001)
		International Search Report (08/25/2003)
		International Search Report (02/05/2004)
		Peyvandi et al., Throm Haemost, Vol. 84, pp. 250-7 (2000)
		Peyvandi et al., Throm Haemost, Vol. 88, pp. 750-5 (2002)
		Soejima et al., Journ of Bio Chem, Vol. 276 (20), pp. 17229-35 (2001)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449
(Rev. 9-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6176.200-US

Serial No. 09/848,107

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Persson et al.

(Use several sheets if necessary)

Filing Date May 3, 2001

Group 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	10/415,963	05/05/03	Ruf et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	97/20939	11/22/96	WO				
	98/31394	01/20/98	WO				
	01/58935 A2	08/16/01	WO				
	01/75086 A2	10/11/01	WO				
	01/82943 A2	11/08/01	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Serial No. 09/848,107

Applicant **Persson et al.**

Filing Date May 3, 2001

Group 1653

**MINER
INITIAL**

**DOCUMENT
NUMBER**

DATE _____

NAME _____

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

DOCUMENT
NUMBER

DATE _____

COUNTRY

CLASS

SUBCLASS

TRANSLATION

YES

NO

01/83725 A1

11/08/01

WO

SUBCLASS

01/85198 A1

11715701

WO

02/22776 A2

03/21/02

WO

02/062376 A1

08/15/02

WO

02/077218 A1

10/03/02

WO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 3-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6176.200-US

Serial No. 09/848,107

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Persson et al.

(Use several sheets if necessary)

Filing Date May 3, 2001

Group 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	02/38162 A1	05/16/02	WO				
	03/027147 A2	04/03/03	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.